Hwang Jae Pil, Lim Ilhan, Na Im Ii, Cho Eung Ho, Kim Byung Ii, Choi Chang Woon, Lim Sang Moo
Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowongil, Nowon Gu, Seoul 139-706 Republic of Korea.
Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowongil, Nowon Gu, Seoul 139-706 Republic of Korea ; Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences (KIRAMS), Nowon Gu, Seoul Republic of Korea.
Nucl Med Mol Imaging. 2014 Jun;48(2):114-20. doi: 10.1007/s13139-013-0255-z. Epub 2013 Dec 6.
The aim of this study is to investigate the prognostic value of F-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography (PET)/computed tomography (CT) in gallbladder cancer patients.
From June 2004 to June 2010, a total of 50 patients with gallbladder cancer who underwent diagnostic staging with F-18 FDG PET/CT following curative or palliative treatments were retrospectively evaluated. For the analysis, all patients were classified by age, sex, maximum standardized uptake value (SUVmax), lymph node (LN) or distant metastasis, serum level of CA19-9 and CEA, type of treatment and American Joint Committee on Cancer (AJCC) stage.
The median survival for the 50 patients was 245 days and the median SUVmax in PET/CT was 8.3 (range, 0-19.7). Patients with SUVmax < 6 survived significantly longer than patients with SUVmax ≥ 6 (median 405 days vs 203 days, p = 0.0400). On Kaplan-Meier analysis, SUVmax (p = 0.0400), stage (p = 0.0001), CA19-9 (p = 0.013), CEA (p = 0.006), LN metastasis (p = 0.0001), distant metastasis (p = 0.0020), type of treatment (p = 0.0001) were significantly associated with overall survival. Multivariate analysis study revealed that the patients with lower SUVmax measured from initial staging PET/CT (p = 0.0380), no LN metastasis (p = 0.0260), a lower stage (p = 0.026) and curative treatment (p = 0.0005) had longer survivals.
The present study shows that SUVmax on F-18 FDG PET/CT can provide prognostic information in patients with gallbladder cancer.
本研究旨在探讨F-18氟脱氧葡萄糖（F-18 FDG）正电子发射断层扫描（PET）/计算机断层扫描（CT）在胆囊癌患者中的预后价值。
回顾性评估2004年6月至2010年6月期间，50例在接受根治性或姑息性治疗后接受F-18 FDG PET/CT诊断分期的胆囊癌患者。为进行分析，所有患者按年龄、性别、最大标准化摄取值（SUVmax）、淋巴结（LN）或远处转移、血清CA19-9和CEA水平、治疗类型及美国癌症联合委员会（AJCC）分期进行分类。
50例患者的中位生存期为245天，PET/CT中的中位SUVmax为8.3（范围0-19.7）。SUVmax＜6的患者生存期明显长于SUVmax≥6的患者（中位生存期405天对203天，p = 0.0400）。根据Kaplan-Meier分析，SUVmax（p = 0.0400）、分期（p = 0.0001）、CA19-9（p = 0.013）、CEA（p = 0.006）、LN转移（p = 0.0001）、远处转移（p = 0.0020）、治疗类型（p = 0.0001）与总生存期显著相关。多变量分析研究显示，初始分期PET/CT测得SUVmax较低（p = 0.0380）、无LN转移（p = 0.0260）、分期较低（p = 0.026）及接受根治性治疗（p = 0.0005）的患者生存期更长。
本研究表明，F-18 FDG PET/CT上的SUVmax可为胆囊癌患者提供预后信息。
